Form 4: Palisade Bio CEO John David Finley Acquires Additional Shares Through Employee Stock Purchase Plan

CEO John David Finley reports the acquisition of 666 shares of Palisade Bio, Inc. through the company's Employee Stock Purchase Plan (ESPP) at a price of $4.9725 per share.

Summary

• John David Finley, CEO, CFO, and Director of Palisade Bio, Inc., acquired 666 shares of common stock on May 20, 2024.
• The shares were purchased through the company's 2021 Employee Stock Purchase Plan (ESPP) at a price of $4.9725 per share.
• Finley also indirectly owns 51 shares through FCW Investments, LLC, where he serves as the managing member with sole investment and voting power.
• Following the transaction, Finley directly owns 7,437 shares of Palisade Bio, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an insider transaction. The CEO's participation in the ESPP could be seen as slightly positive, indicating confidence, but it's not a major event.

Positives

• The CEO's participation in the ESPP could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the trading activities of company executives and directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Employee Stock Purchase Plans are a common benefit offered by companies to incentivize employee ownership.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders. It provides transparency to shareholders regarding insider trading activity.

Key Dates

Keywords

Palisade Bio, PALI, John David Finley, ESPP, Employee Stock Purchase Plan, Beneficial Ownership, Form 4, SEC, FCW Investments LLC